1. Home
  2. QCLS vs BTAI Comparison

QCLS vs BTAI Comparison

Compare QCLS & BTAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

QCLS

Q/C Technologies Inc.

HOLD

Current Price

$2.75

Market Cap

31.1M

Sector

Health Care

ML Signal

HOLD

Logo BioXcel Therapeutics Inc.

BTAI

BioXcel Therapeutics Inc.

HOLD

Current Price

$0.85

Market Cap

27.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
QCLS
BTAI
Founded
2014
2017
Country
United States
United States
Employees
2
N/A
Industry
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
31.1M
27.7M
IPO Year
N/A
2018

Fundamental Metrics

Financial Performance
Metric
QCLS
BTAI
Price
$2.75
$0.85
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$23.00
AVG Volume (30 Days)
182.2K
1.4M
Earning Date
04-15-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
75.63
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$197.82
Revenue Next Year
N/A
$910.15
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.50
$0.74
52 Week High
$8.17
$8.08

Technical Indicators

Market Signals
Indicator
QCLS
BTAI
Relative Strength Index (RSI) 34.79 41.33
Support Level $2.53 $0.74
Resistance Level $3.90 $1.41
Average True Range (ATR) 0.23 0.07
MACD -0.06 0.00
Stochastic Oscillator 24.47 35.48

Price Performance

Historical Comparison
QCLS
BTAI

About QCLS Q/C Technologies Inc.

Q/C Technologies Inc is engaged in building blockchain and cryptocurrency infrastructure that is faster and more energy-efficient through quantum-class laser-based computing. The company uses laser-based processors inspired by quantum technology that can solve complex problems. By combining photonic computing with cryptocurrency systems, the company creates powerful and sustainable solutions for the next generation of blockchain applications.

About BTAI BioXcel Therapeutics Inc.

BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are-BXCL501, being evaluated as a potential treatment for agitation associated with multiple neurological disorders and BXCL701, an investigational oral innate immune activator for the treatment of aggressive forms of prostate cancer and other solid and liquid tumors. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.

Share on Social Networks: